U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H17Br2NO2.ClH.H2O
Molecular Weight 433.564
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEMBREXINE HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.O[C@H]1CC[C@@H](CC1)NCC2=CC(Br)=CC(Br)=C2O

InChI

InChIKey=GZLZRWMDTSWUDJ-SOBFFWEGSA-N
InChI=1S/C13H17Br2NO2.ClH.H2O/c14-9-5-8(13(18)12(15)6-9)7-16-10-1-3-11(17)4-2-10;;/h5-6,10-11,16-18H,1-4,7H2;1H;1H2/t10-,11-;;

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C13H17Br2NO2
Molecular Weight 379.088
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3363832 | http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013623.pdf

Dembrexine is a mucolytic agent which reduces the viscosity of respiratory mucus. It improves movement of mucus in small airways. Dembrexine increases secretion of the serous cells in the glands of the nasal, tracheal and bronchial cells and in type II alveolar cells. It also possesses an anti-tussive effect. Dembrexine is used in the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.

Originator

Boehringer Ingelheim
130
Curator's Comment: # Boehringer Ingelheim Gmbh

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1447
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Sputolosin

Approved Use

The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Palliative
Approved
8583
Sputolosin

Approved Use

The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Palliative
Approved
8583
Sputolosin

Approved Use

The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Palliative
Approved
8583
Sputolosin

Approved Use

The agent is indicated for the treatment of foal pneumonia.
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
OTHER GOV'T
https://www.hpra.ie/img/uploaded/swedocuments/Licence_VPA10454-014-001_23112018150029.pdf
0.3 mg/kg bw single, oral
dose: 0.3 mg/kg bw
route of administration: Oral
experiment type: SINGLE
co-administered:
DEMBREXINE plasma
Equus caballus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
The mucolytic effect of Sputolosin in horses with respiratory disease.
1988-01-30
The trans-cis isomerization of trans-4'-(2-hydroxy-3,5-dibromo-benzylamino)cyclohexanol in vivo and in vitro in different species.
1986-07
Patents

Patents

US4073942
3
US4113777 A
3

Sample Use Guides

In Vivo Use Guide
Twice daily administration of 0.3 mg active ingredient per kg bodyweight. Adult horses (500 kg): 30 g powder twice daily in the food. Small horses, ponies and foals: 10 g powder per 170 kg bodyweight twice daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:34:15 GMT 2025
Edited
by admin
on Mon Mar 31 19:34:15 GMT 2025
Record UNII
SZ936TIM8E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEMBREXINE HYDROCHLORIDE MONOHYDRATE FOR VETERINARY USE
EP  
Preferred Name English
DEMBREXINE HYDROCHLORIDE MONOHYDRATE
Common Name English
TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL)AMINO)CYCLOHEXANOL HYDROCHLORIDE MONOHYDRATE
Systematic Name English
DEMBREXINE HYDROCHLORIDE MONOHYDRATE FOR VETERINARY USE [EP MONOGRAPH]
Common Name English
Code System Code Type Description
SMS_ID
300000029157
Created by admin on Mon Mar 31 19:34:15 GMT 2025 , Edited by admin on Mon Mar 31 19:34:15 GMT 2025
PRIMARY
FDA UNII
SZ936TIM8E
Created by admin on Mon Mar 31 19:34:15 GMT 2025 , Edited by admin on Mon Mar 31 19:34:15 GMT 2025
PRIMARY
Related Record Type Details
Structure of DEMBREXINE
PARENT -> SALT/SOLVATE
Structure of DEMBREXINE HYDROCHLORIDE
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of DEMBREXINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966